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Abstract
Membrane permeabilization by Islet Amyloid Polypeptide (IAPP) is suggested to be the main mechanism
for IAPP-induced cytotoxicity and death of insulin-producing -cells in type 2 diabetes mellitus (T2DM).
The insoluble fibrillar IAPP deposits (amyloid) present in the pancreas of most T2DM patients are not the
primary suspects responsible for permeabilization of -cell membranes. Instead, soluble IAPP oligomers
are thought to be cytotoxic by forming membrane channels or by inducing bilayer disorder. In addition, the
elongation of IAPP fibrils at the membrane, but not the fibrils themselves, could cause membrane
disruption. Recent reports substantiate the formation of an -helical, membrane-bound IAPP monomer as
possible intermediate on the aggregation pathway. Here, the structures and membrane interactions of
various IAPP species will be reviewed, and the proposed hypotheses for IAPP-induced membrane
permeabilization and cytotoxicity will be discussed.
Keywords
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2Introduction
Human Islet Amyloid Polypeptide (hIAPP) is a peptide that forms insoluble fibrillar deposits (amyloid)
in the pancreas of patients with type 2 diabetes mellitus (T2DM). hIAPP is produced and secreted, together
with insulin, by the -cells in the pancreatic Islets of Langerhans. Monomeric hIAPP is suggested to be a
hormone with roles in gastric emptying and regulation of glucose homeostasis (Karlsson 1999). Although
little details are known about the precise physiological function of hIAPP, there are indications that hIAPP
binds to specific membrane-located receptors (Hay, et al. 2004). Recently, a non-amyloidogenic synthetic
hIAPP variant, called pramlintide or symlin, has been commercially introduced as an additional therapeutic
approach for diabetes patients (Riddle, et al. 2006).
More than 90% of T2DM patients have hIAPP amyloid in their Islets of Langerhans, as determined by
post-mortem analysis. The presence of islet amyloid in T2DM has been linked to death of the insulin-
producing -cells, thereby contributing to the development of this disease (Höppener, et al. 2000). T2DM
can be classified as a protein-misfolding disease, and it shares the debilitating consequences of misfolded
and aggregated peptides and proteins with more than 20 other diseases, such as Alzheimer’s disease,
Parkinson’s disease and prion diseases (Chiti, et al. 2006). The interaction of hIAPP with -cell membranes
is thought to play a crucial role in hIAPP cytotoxicity and death of the insulin-producing -cells. Amyloid-
membrane interaction is not only relevant for cytotoxicity in T2DM, but considered to be a generic
mechanism for amyloid-induced cytotoxicity in most of the amyloid-related diseases (Glabe, et al. 2006;
Lashuel, et al. 2006).
In this review, the current knowledge of hIAPP-membrane interactions will be presented and analysed,
with a focus on the role of hIAPP-membrane interaction in relation to mechanisms of cytotoxicity. Various
suggested hypotheses for hIAPP-induced membrane permeabilization will be discussed. In addition, the
current insight into the structural characteristics of hIAPP assemblies and of membrane-bound hIAPP will
be reviewed.
Different appearances of hIAPP: monomer, oligomer and amyloid fibril
The 37-residue hIAPP peptide can appear in various aggregation states, i.e. monomer, oligomer or fibril
(polymer), all with very different structures (Fig. 1). It has now become clear that oligomers and fibrils are
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different sizes, shapes (polymorph), and with variations in secondary, tertiary and quaternary structure.
Many different expressions are in use to indicate “oligomers”, such as prefibrillar aggregates, micelles and
ADDLs, and it has proven difficult to distinguish different populations of oligomers (Glabe 2008). For the
purpose of this review the term oligomer will be used to describe hIAPP species that are composed of 2 to
approximately 60 hIAPP monomers (~ 250 kDa). Some important questions regarding these different
species are the topic of many recent papers: What is the structure of the various hIAPP species detected?
Which hIAPP species are cytotoxic and present in vivo? A particularly important question regarding the
scope of this review is: how do these different hIAPP species interact with a membrane? These and related
questions will be addressed in the next sections. First, the structure of several aggregation states of hIAPP
will be discussed.
Of the various hIAPP species, the structure of fibrillar hIAPP is best known despite it being the most
insoluble one. The stable nature of hIAPP fibrils has likely contributed to the relative ease of handling and
studying it; hIAPP fibrils are not degraded by proteases and generally need harsh conditions for
depolymerization, like the use of concentrated formic acid or organic solvents (Clark, et al. 1987). In
contrast, the study of the structure of monomeric and oligomeric hIAPP in physiological buffers has been
hampered by their instability and fast ‘spontaneous’ aggregation. The large majority of the structural
information about hIAPP fibrils stems from in vitro assembled fibrils, the production of which mostly
requires nothing more than dissolving hIAPP monomer in a physiological buffer and keeping it for hours to
days.
Advanced methods, in particular electron microscopy (EM), electron paramagnetic resonance
spectroscopy (EPR), X-ray diffraction, and nuclear magnetic resonance spectroscopy (NMR) have
significantly improved our understanding of hIAPP fibril structure (Goldsbury, et al. 2000; Jayasinghe, et
al. 2004; Sumner Makin, et al. 2004; Luca, et al. 2007). In vitro produced fibrils of hIAPP or hIAPP
fragments, even from the same sample, display various cross- structures (Madine, et al. 2008) and
morphologies (Goldsbury, et al. 1997; Sumner Makin, et al. 2004; Radovan, et al. 2008), for example
coiled fibrils and ribbon-like fibrils (Fig. 1b). The parallel, in register structure of hIAPP fibrils was first
demonstrated by EPR spectroscopy (Jayasinghe, et al. 2004). The most recent and most detailed model for
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molecules that form a parallel -sheet structure running perpendicular to the length axis of the fibril (Fig.
1c) (Luca, et al. 2007). Residues 8 to 17 and 28 to 37 form the -sheet structure, whereas residues 1 to 7 are
largely unstructured. Importantly, this model is based on experimental data of a morphologically
homogeneous sample of hIAPP fibrils, so called striated ribbons.
Another model of the hIAPP fibril suggests that the fibril is composed of three protofilaments, each
based on stacking of single hIAPP molecules in which residues 9 to 37 participate in a planar S-shaped fold
forming the -sheet structure (Kajava, et al. 2005). Most proposed models, combined with aggregation
studies on hIAPP fragments, place residues 9 to 37 in the amyloidogenic core (Nilsson, et al. 1999;
Jaikaran, et al. 2001; Scrocchi, et al. 2003; Gilead, et al. 2008; Wiltzius, et al. 2008), which adjusts the
historic view that only residues 20 to 29 would be important for amyloid formation (Westermark, et al.
1990). Different models are likely required to account for the various hIAPP fibril morphologies that are
commonly observed. Studies of hIAPP fibrils in pancreatic islets show that their morphological character is
grossly the same as that of in vitro produced fibrils (Westermark 1973; de Koning, et al. 1994; Jaikaran and
Clark, 2001), but even large-scale features of in vivo fibrils, like the number of protofibrils, are unknown.
Consequently, an important question that remains to be answered is which fibril morphology is present in
or near the -cell? Additionally, which fibril morphology is related to cytotoxicity, or results from
cytotoxic oligomers?
Compared to the detailed structural information available for hIAPP fibrils, the information about the
structure of hIAPP oligomers is much sparser and considerably less detailed. All our knowledge of the
hIAPP oligomer structure comes from in vitro produced oligomers. A protocol for the in vitro production of
hIAPP oligomers entails stirring freshly dissolved, supposedly monomeric hIAPP at 500 rpm in an
eppendorf tube, at pH ~ 3, for 24 to 48 hrs at 22°C (Kayed, et al. 2004). This process results in a
homogeneous sample of spherical hIAPP oligomers, 3-5 nm in diameter, as observed by EM (Fig. 1d).
Others have detected, either directly or indirectly, the presence of hIAPP oligomers as transient species in
samples of fibril forming hIAPP, with large variations in shape and size, ranging from a cluster of a 10-20
hIAPP monomers to more than 500 (Janson, et al. 1999; Anguiano, et al. 2002; Porat, et al. 2003; Green, et
al. 2004). An example of a ring-shaped hIAPP oligomer is shown in figure 1e (Porat, et al. 2003).
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suggestions that hIAPP oligomers are off-pathway, meaning that they are not on a productive route towards
hIAPP fibrils (Meier, et al. 2006; Haataja, et al. 2008). Others suggest that hIAPP oligomers are consumed
during hIAPP fibril growth, suggesting that the oligomers are on-pathway (Anguiano, et al. 2002; Porat, et
al. 2003; Green, et al. 2004; Knight, et al. 2006). This is a crucial issue since toxic off-pathway oligomers
could become increasingly populated when a therapeutic strategy based on inhibition of on-pathway hIAPP
oligomers and/or fibrils would be used. Considering the observed variation in size and character of
oligomers, it is not unthinkable that both on- and off pathway hIAPP oligomers co-exist.
A significant finding that has helped in detecting and characterizing hIAPP oligomers has been the
realization of an oligomer-specific antibody (Kayed, et al. 2003). The observation that this anti-oligomer
antibody, named A-11, recognizes hIAPP oligomers but not hIAPP monomers or hIAPP fibrils suggests
that these oligomers are structurally unique, and different from hIAPP fibrils. Moreover, the A-11 antibody
also binds specifically to oligomers of other amyloid-related peptides and proteins, suggesting a common
structural motive and possibly a key to a generic mechanism of cytotoxicity in misfolding diseases. Two
other antibody/antisera have been produced against hIAPP oligomers: the I-11 antibody reacts to the same
hIAPP oligomers as A-11 (Meier, et al. 2006), whereas the antiserum APF specifically recognizes the
bigger, annular hIAPP oligomers (Kayed, et al. 2009). The use of aggregation-state specific antibodies is
expected to reveal more structural characteristics of hIAPP species on the aggregation pathway in future
studies.
The structural information about the hIAPP monomer is very limited. Monomeric hIAPP, in the
majority of studies produced synthetically, is characterized as a natively unfolded peptide, showing
typically unstructured circular dichroism (CD) spectra (Goldsbury, et al. 2000; Higham, et al. 2000).
Recent NMR experiments suggest that the hIAPP peptide chain is unfolded, although part of the chain,
approximately residues 8 to 19, can dynamically adopt -helical structure (Williamson, et al. 2007;
Yonemoto, et al. 2008; Wei, et al. 2009). The spontaneous and fast aggregation of monomeric hIAPP in an
aqueous environment – insoluble fibrils are formed within a few hours – forms a major obstacle for
studying the structural characteristics of monomeric hIAPP in solution. Addition of SDS or binding to a
membrane (as will be discussed later) results in stabilized, mostly -helical, monomeric hIAPP states
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suggested to increase the helical tendency of hIAPP (Wei, et al. 2009), although this interaction seems to be
very dependent on the physical forms of hIAPP and insulin, i.e. soluble or fibrillar hIAPP and soluble or
crystalline insulin (Knight, et al. 2008). Both insulin and lipids thus seem to induce helical structure, but
surprisingly their effect on hIAPP aggregation is opposite. Lipids have a tendency to promote hIAPP
aggregation (Knight, et al. 2004) whereas insulin is well known as an inhibitor of hIAPP fibril formation
(Westermark, et al. 1996). The effect of lipids and insulin on the secondary structure of hIAPP monomers
in vitro could suggest that hIAPP might be structured under in vivo conditions through interaction with
physiological binding partners (insulin and lipids are both present in secretory vesicles, the cellular storage
of hIAPP and insulin).
Islet amyloid fibrils at the -cell membrane
Just after the discovery of hIAPP as the major component of islet amyloid in 1987 (Cooper, et al. 1987;
Westermark, et al. 1987), it was generally thought that hIAPP fibrils were cytotoxic to -cells, thereby
contributing to T2DM (Clark, et al. 1987; Lorenzo, et al. 1994). Interestingly, already in the early seventies
a peculiar interaction between extracellular islet amyloid fibrils and -cell membranes had been noticed
(Fig. 2) (Westermark 1973). It was observed then, and confirmed in later studies, that the islet amyloid
fibrils were often orientated perpendicular to the membrane, and co-localized with distinct changes in the
morphology of the -cell membrane (Westermark 1973; Clark, et al. 1987; Jaikaran and Clark, 2001). In
contrast, in the vicinity of other types of Islet cells (e.g. -cells), this characteristic orientation of fibrils
near membranes was rarely seen, and fibrils were mostly randomly orientated. Whereas these studies
involved endogenous hIAPP, also externally added, freshly dissolved, synthetic hIAPP added to cultured -
cells induced typical membrane deformations, for example membrane invaginations, budding and vesicle
formation (Lorenzo, et al. 1994; Janson, et al. 1999; Saafi, et al. 2001; Casas, et al. 2008).
It appeared that the amount of amyloid in the Islets of Langerhans did not correlate well with the
decrease in the number of healthy -cells, pointing to species other than fibrils being the culprit. Currently,
the prevailing and well-documented view is that soluble hIAPP oligomers are the toxic species and that
hIAPP fibrils are biologically inert (Haataja, et al. 2008). With the increase in knowledge of the
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understanding of their interaction with membranes. The mechanism of hIAPP oligomer cytotoxicity is
thought to involve permeabilization of cellular membranes, possibly through formation of membrane pores.
Several variations of this hypothesis have been proposed and will be discussed in the next section.
Membrane permeabilization by hIAPP oligomers
The first observation that soluble amyloid oligomers could affect the integrity of a lipid bilayer by
forming an ion-channel, was made in 1993 (Arispe, et al. 1993). It was shown that A, the Alzheimer
related amyloidogenic protein, could form cation-selective channels in planar lipid bilayers. Soon after that,
the group of Kagan showed that also hIAPP could form cation-selective channels (Mirzabekov, et al.
1996). In contrast, the non-amyloidogenic rIAPP did not form channels. Currently, a substantial amount of
experimental data suggests that hIAPP, as well as many other amyloid-related peptides and proteins, can
form cation-selective channels. (Kawahara, et al. 2000; Kourie, et al. 2002; Kagan, et al. 2004).
Visualization by atomic force microscopy (AFM) suggests that a hIAPP ion-channel, assembled in a
bilayer, is composed of approximately 5 subunits in a circular arrangement (Fig. 1f) (Quist, et al. 2005).
Various sizes of the hIAPP-induced membrane pores or openings have been suggested, ranging from
Ca2+-permeable to permeable for fluorescent dyes with a size larger than 1 kDa (Anguiano, et al. 2002;
Demuro, et al. 2005; Kagan 2005). Soluble hIAPP oligomers, and amyloid oligomers in general, could
have characteristics of pore-forming protein toxins, like -hemolysin, and might have a similar mechanism
of action (Lashuel, et al. 2002; Lashuel, et al. 2006; Kayed, et al. 2009). Several groups have reported that
membrane permeabilization is caused by hIAPP oligomer-induced distortions of the phospholipid bilayer
packing and membrane instability, in contrast to the formation of discrete pores (Janson, et al. 1999;
Kayed, et al. 2004). Another possibility of oligomer-induced membrane permeabilization is the interaction
of amyloid oligomers with specific membrane receptors, which has been shown for HypF-N aggregates
(Pellistri, et al. 2008), but not (yet) for hIAPP.
Recently, it was shown that an A-11 positive hIAPP oligomer can be converted into a larger and more
stable annular hIAPP oligomer (also known as “annular protofibril”) catalysed by the presence of
hydrophobic/hydrophilic interfaces, in particular lipid bilayers (Kayed, et al. 2009). Interestingly, these two
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higher membrane permeabilizing activity and being more toxic compared to the bigger annular oligomer.
Although the conclusions of this work still seem preliminary, it shows the direction of future research:
solving the heterogeneity in oligomer types and determining which type of oligomer is cytotoxic and
physiologically relevant. One of the most challenging tasks in this route is to obtain samples of oligomers
with a single morphology and high purity.
Many aspects of the structure and formation of hIAPP oligomers are unknown. The secondary structure
of hIAPP oligomers is not well described, and both -sheet rich hIAPP oligomers (Kayed, et al. 2009) and
-helix rich hIAPP oligomers have been observed (Knight, et al. 2006). An -helical structure of hIAPP
oligomers is plausible as helical structure is observed upon binding of monomeric hIAPP to membranes, as
will be discussed later. In addition, hIAPP monomers in solution are observed to sample the helical state.
However, conversion of on-pathway, -sheet rich oligomers to cross- structured fibrils seems
energetically more favorable than conversion of -helical oligomers. Contradicting reports have appeared
suggesting that hIAPP oligomer assembly occurs either at the membrane (Quist, et al. 2005; Knight, et al.
2006) or in solution, after which the pre-formed oligomers interact with the membrane (Kagan, et al. 2004;
Kayed, et al. 2004). Figure 3 schematically shows the proposed variety in oligomer secondary structure,
membrane permeabilization events, and the various suggested routes for the assembly of soluble hIAPP
monomers into larger structures, oligomers and fibrils at or near the membrane.
Concerns about the toxic oligomers hypothesis
The “toxic-oligomer hypothesis” described above is well-documented and supported, not only for
hIAPP but also for other amyloid forming peptides and proteins related to misfolding diseases. However,
recent reports suggesting alternative hypotheses have emerged, indicating that the mechanism of hIAPP-
membrane interaction as an explanation for cytotoxicity is far from understood. Several notions justify
concerns about the hypothesis that hIAPP oligomers are involved in membrane permeabilization and
cytotoxicity.
First, whereas hIAPP fibrils have been unambiguously isolated and identified from in vivo sources, the
evidence for the existence of toxic hIAPP oligomers in vivo is extremely scarce, if not absent. The only
9indication is the detection of A-11-positive hIAPP oligomers in Islets of hIAPP-transgenic mice (Lin, et al.
2007). It has not yet been shown that these hIAPP oligomers are actually cytotoxic in vivo. Moreover, A-
11-positive oligomers have not (yet) been identified in diabetic patients, although there is evidence for
A11-positive oligomers in vivo in relation to other diseases like Alzheimer’s disease (Koffie, et al. 2009).
Difficulties in detecting hIAPP oligomers in vivo could arise due to instability of hIAPP oligomers,
specifically in tissue sections. In addition, the A-11 antibody is reported to be ineffective in paraffin-
embedded tissue (Haataja, et al. 2008).
Second, one should be cautious in interpreting results of cytotoxicity assays in which “toxic” hIAPP
oligomers are incubated with cells for prolonged periods. Unless it is established that these oligomers
remain unaltered during the entire period of incubation, the oligomers could convert into other species,
which might be the actual toxic species. It has been suggested that inhibition of hIAPP fibril formation by
rifampicin does not prevent -cell death, and instead hIAPP oligomers are cytotoxic (Meier, et al. 2006).
However, it was recently reported that rifampicin interferes with Thioflavin T measurements, thereby
negatively affecting tests for the toxicity of hIAPP fibrils (Meng, et al. 2008).
A third reason that questions the toxic oligomer hypothesis regarding hIAPP is the emergence of studies
that report difficulties in detecting hIAPP oligomers under in vitro conditions. Analytical ultra
centrifugation experiments could not detect hIAPP oligomers smaller than 100 monomers (Vaiana, et al.
2008), which is much bigger than has been suggested before (Kayed, et al. 2004). In some studies it has
been proposed that events or species other than hIAPP oligomers could induce membrane disruption or
permeabilization (Green, et al. 2004; Sparr, et al. 2004).
Finally, reports have emerged suggesting that amyloid fibrils composed of various peptides and
proteins, for example A (Okada, et al. 2007), prion protein (Novitskaya, et al. 2006), lysozyme
(Gharibyan, et al. 2006), and ure2p (Pieri, et al. 2006) might be toxic after all. An interesting case is that of
ure2p, whose native like fibrils are shown to be cytotoxic, possibly via interaction of certain structural
features with the membrane. A heat treatment of these fibrils however renders them unable to interact with
the membrane and abolishes cytotoxicity (Pieri, et al. 2006). These observations indicate that cytotoxicity
of fibrils could depend on fibril structure and/or fibril morphology. Fibrils could also be a source for the
formation of potentially cytotoxic, fibril-derived species, although this has not (yet) been reported for
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hIAPP. Amyloid fibrils can break, as shown for insulin fibrils (Smith, et al. 2006), and monomers or
oligomers could dissociate from fibrils, as shown for fibrils formed from an SH3 domain (Carulla, et al.
2005). Importantly, lipids are able to promote fibril dissociation into cytotoxic oligomers (Martins, et al.
2008).
Membrane permeabilization by the process of hIAPP aggregation, rather than by hIAPP species
A recent study suggests that it is not a specific (oligomeric) hIAPP species, but the process of hIAPP
fibril growth at the membrane that causes membrane permeabilization (Engel, et al. 2008). It was found
that the assembly of hIAPP fibrils at the membrane causes membrane disruption, possibly by forcing the
curvature of the bilayer to unfavorable angles (Fig. 4), or by the uptake of lipids by hIAPP fibrils during
fibril elongation at the membrane. Importantly, this study shows that pre-formed hIAPP fibrils and the non-
amyloidogenic rIAPP do not permeabilize membranes, whereas allowing hIAPP to aggregate at the
membrane, starting from a monomeric hIAPP population, leads to fibril growth at the membrane and
concomitant membrane permeabilization. The uptake of lipids into forming amyloid has been observed
before under in vitro conditions (Sparr, et al. 2004; Zhao, et al. 2004; Domanov, et al. 2008), and also in
various types of amyloid that was isolated from patients (Gellermann, et al. 2005; Gellermann, et al. 2006).
The tendency of amyloidogenic peptides to fibrillate on the surface of lipid vesicles, and simultaneously
damage the lipid bilayer, has also been observed using molecular dynamics simulations (Friedman, et al.
2009). Remarkably, it was found in this simulation that bilayer permeabilization is caused by growing
aggregates, but not by mature fibrils, in agreement with the hypothesis that hIAPP fibril growth at the
membrane causes membrane damage (Engel, et al. 2008).
The hypothesis that cytotoxicity is related to fibril growth at the membrane requires more investigation
and importantly, validation in a cellular environment. However, it is important to keep in mind the early
observation of in vivo interactions of Islet amyloid fibrils with -cells and the resulting significant changes
in membrane morphology, including changes in the curvature (see Fig. 2 and the earlier section “Islet
amyloid fibrils at the -cell membrane”). These hIAPP-induced effects on membrane morphology were
also observed in model membrane studies (Domanov, et al. 2008), and are straightforward to explain using
the hypothesis of fibril growth at the membrane (Engel, et al. 2008). The possibility that amyloid fibrils are
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able to physically ‘break’ cell membranes was recently suggested in a study that showed that fibrillar
polyglutamine can be taken up by cells (Ren, et al. 2009).
Fibril growth at the membrane as a membrane-permeabilizing action has not only been suggested for
hIAPP, but also for other amyloidogenic proteins, such as the Alzheimer’s disease related Abeta (Yip, et al.
2001; Wogulis, et al. 2005). Interestingly, the suggestion that not an hIAPP oligomer, but the membrane-
located conversion of small spherical oligomers into annular oligomers might be responsible for membrane
permeabilization (Kayed, et al. 2009) also supports the notion that a process occurring at the membrane
could lead to membrane permeabilization. Interestingly, most pore-forming toxins, which have been
hypothesized to have a similar mechanism of action as hIAPP oligomers (Glabe, et al. 2006; Lashuel, et al.
2006), are formed from their monomeric units at the membrane interface and not in solution (Gonzalez, et
al. 2008). This includes the bacterial pore-forming toxin -hemolysin which also reacts with the annular
oligomer antiserum (Kayed, et al. 2009). This again suggests that toxicity might be related to a process or a
conversion occurring at the membrane, and not to a certain species. These new ideas might lead to a focus
on mechanisms of membrane permeabilization that are governed by conversions of species along the fibril
formation pathway. In such mechanisms, membranes could have an important function as mediator or
accelerator of the conversion of one hIAPP species to the other, possibly representing a cytotoxic event.
The role of interfaces in hIAPP aggregation
Membranes have the ability to catalyse hIAPP fibril formation. More precisely, the presence of
phospholipid bilayers can reduce the lag-phase of hIAPP fibril formation, an effect that is most pronounced
with negatively charged lipids (Knight, et al. 2004; Jayasinghe, et al. 2005; Knight, et al. 2006). Other
negatively charged surfaces, like heparin molecules, are also able to catalyse hIAPP aggregation (Konno, et
al. 2007). The observation that a dichloromethane/water interface accelerates hIAPP fibril formation seems
to indicate that next to charge, also hydrophobicity at the interface plays an important role in the
acceleration of hIAPP aggregation (Ruschak, et al. 2007). Even hIAPP fibrils themselves can accelerate
subsequent hIAPP fibril formation, a process that is known as secondary nucleation (Padrick, et al. 2002).
The effects of these interfaces on hIAPP aggregation and fibril formation add another complicating
dimension to amyloid-membrane interactions, and indicate that hIAPP-induced membrane permeabilization
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is closely intertwined with interface-mediated hIAPP aggregation. In addition, it has been suggested that
other factors can significantly affect the interaction between hIAPP and membranes, for example calcium
ions (Sciacca, et al. 2008) and crystalline insulin (Knight, et al. 2008).
Interfaces can affect the aggregation of peptides and proteins in different ways. Interfaces can serve as a
template that helps put molecules in a preferential orientation such that aggregation is favored, as has been
suggested for hIAPP (Knight, et al. 2004). Membrane fluidity is suggested to be an important factor that
enables a specific orientation of fibrils on membranes (Zhang, et al. 2008). Secondly, adsorption of the
peptide at the interface can locally increase the peptide concentration, resulting in two-dimensional
crowding (Aisenbrey, et al. 2008). Consequently, a high local concentration of membrane-bound hIAPP
monomers will greatly accelerate aggregation. In addition, interaction or aggregation of membrane-bound
hIAPP monomers could result in cooperative binding (Knight, et al. 2004). Thirdly, interfaces have the
ability to change the conformation of a protein (Norde, et al. 1991; Engel, et al. 2004) and consequently
might also induce structure in a protein or peptide that is unstructured in solution, like hIAPP. Indeed, it has
been shown that adsorption of hIAPP at membranes induces helical structure, as will be discussed in detail
in the next section. Interfaces also have a significant effect on the conformation and nucleation of
amyloidogenic proteins (Giacomelli, et al. 2005; Linse, et al. 2007). Possibly, membranes could induce
different fibril morphologies, an observation that was made for apolipoprotein fibrils (Griffin, et al. 2008).
Recent reviews address the interaction of amyloidogenic peptides and proteins with various interfaces and
in particular membranes (Gorbenko, et al. 2006; Stefani 2007; Aisenbrey, et al. 2008; Relini, et al. 2009).
The effect of interface-mediated catalysis of aggregation might be a very important factor in the
mechanism of amyloid-induced cytotoxicity. With membranes acting as a ‘template’ for amyloid
aggregation, it is not surprising that amyloid species, through their conversion, also affect the barrier
properties of the bilayer.
Residue-level details of hIAPP interacting with lipid bilayers
hIAPP has several positively-charged residues, all of which are located on the N-terminal side of the
peptide (Fig. 1a). These N-terminal residues are suggested to be involved in the initial interaction of hIAPP
with lipids, in particular negatively charged lipids (Knight, et al. 2004; Engel, et al. 2006; Lopes, et al.
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2007). Indeed it has been shown that membrane binding of hIAPP is most efficient when bilayer lipids are
negatively charged (Knight, et al. 2006; Apostolidou, et al. 2008; Brender, et al. 2008). Still, electrostatic
interactions are certainly not the only interactions involved. As discussed in the previous section,
hydrophobic interactions also most likely play an important role. Remarkably, the 7 N-terminal residues,
including the disulfide, are not required for hIAPP cytotoxicity (Zhang, et al. 2003).
The residues important for hIAPP-membrane interaction could include those residues that are different
compared to the non-amyloidogenic rIAPP. These six residues (marked red in figure 1a) are all suggested
to be part of the amyloidogenic core of hIAPP and thus important for the formation of fibrils. The only
charged residue of these six is histidine 18, which is important for both fibril formation (Abedini, et al.
2005) and membrane interaction (Nanga, et al. 2008). Deprotonation of H18 favors an orientation of the
hIAPP1-19 fragment parallel to the membrane, while in the protonated state hIAPP1-19 is suggested to be
transmembrane (Nanga, et al. 2008). Importantly, the first 17 N-terminal residues are identical in hIAPP
and rIAPP, and seem surprisingly well conserved in IAPP from several species (Nishi, et al. 1989). The N-
terminal region has been suggested to be involved in binding to receptors (Bhogal, et al. 1993) and binding
to insulin (Gilead, et al. 2006; Wei, et al. 2009).
Recent reports suggest that hIAPP fiber formation and hIAPP-induced membrane disruption are
separate processes localized in two distinct regions of the peptide (Brender, et al. 2008; Brender, et al.
2008). It was suggested that membrane disruption is caused by the N-terminal section of hIAPP (residues
1-19), and that amyloidogenicity is not required for this. This is unexpected since many reports have shown
a clear link between amyloidogenicity and membrane permeabilization, not only for hIAPP but for many
other amyloidogenic proteins as well (see previous sections). In particular, it has been unambiguously
shown that the cytotoxicity of hIAPP is linked to its amyloidogenicity, in contrast to non-amyloidogenic
rIAPP that is not cytotoxic and not linked to T2DM (Lorenzo, et al. 1994; Höppener, et al. 2000). A
possible explanation for the membrane disrupting ability of non-amyloidogenic hIAPP fragments, as
observed in the studies by the group of Ramamoorthy (Brender, et al. 2008; Brender, et al. 2008), as well as
of rIAPP (Green, et al. 2004; Knight, et al. 2006), is the ‘carpet mechanism’, in which -helical peptides
disrupt membranes without the need to aggregate into -sheet–rich structures (Shai 1999). Indeed, hIAPP
and rIAPP both insert in lipid monolayers as monomer (Engel, et al. 2006; Lopes, et al. 2007), and their
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similar membrane interaction has been ascribed to the carpet mechanism (Green, et al. 2004). Membrane
damage by rIAPP and non-amyloidogenic hIAPP fragments seems to occur only in membranes solely
composed of negatively charged lipids, conditions that are very different from those found in cells
(approximately 20 to 30% negatively charged lipids). Moroever, experimental conditions, for instance
different membrane permeability assays, or the presence or absence of an amidated C-terminus, can lead to
discrepancies between studies. In conclusion, since membrane damage under certain conditions can be
induced by the T2DM-unrelated and non-amyloidogenic rIAPP, it is unlikely that the mechanism for this
membrane damage relates to a physiologically relevant event that can explain membrane damage and
cytotoxicity in T2DM.
Apart from the N-terminus, it has been shown that other residues are in contact with the membrane
when hIAPP binds to a phospholipid bilayer. Important information comes from a recent residue-level
study using site-directed spin labeling and EPR spectroscopy. This study shows details of the -helical
structure of monomeric hIAPP bound to large unilamellar vesicles (LUVs) composed of 80% POPS and
20% POPC (Apostolidou, et al. 2008). It was found that residues 9 to 22 form an -helix oriented parallel
to the membrane surface, embedded in the bilayer at the level of the phospholipid headgroups (Fig. 5).
Importantly, most of these residues are also thought to be involved in the formation of cross- structure in
the hIAPP fibril (Fig. 1c). This might explain the success of the study since the high amount of negatively
charged lipids trapped this helical state, possibly by preventing key residues from conversion to -sheet
structure. It was also suggested that residues Thr9, Leu12, Leu16 and Ser20 face the hydrophobic core of
the membrane, while the charged residues Arg11 and His18 are located at the level of the phospholipid
headgroups (Fig. 5). Residues 23-37 of the membrane-bound hIAPP are largely unstructured, and it is
implied that this exposure will promote conversion to -sheet structure (Apostolidou, et al. 2008). It should
be noted that the presence of 80% negatively charge lipids is very different from the in vivo situation
(~25% negatively charged lipids), consequently this helical state is likely to be less stable in a cellular
environment. Still, the observation that physiological levels of negatively charged lipids (~25%) are
sufficient to accelerate hIAPP fibril formation (Jayasinghe, et al. 2005) supports the notion that transient
helical structure might play a role in hIAPP fibrillation in vivo. In this context it is important to note that
negatively charged lipids are preferentially located at the cytosolic side of the cellular membrane, where
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they are only available to intracellular hIAPP species. Consequently, membrane permeabilization by the
process of fibril growth at the membrane (Engel, et al. 2008), which occurs independent of the presence of
negatively charged lipids, could affect biological membranes from both sides. The previously mentioned
EPR study confirms earlier work, which had shown using CD and FTIR spectroscopy that hIAPP adopts
helical structure when sufficient negatively charged lipids are present (Jayasinghe, et al. 2005; Knight, et al.
2006; Lopes, et al. 2007).
Considering that residues 9-22, except for residue 18, are identical for hIAPP and rIAPP, it is not
surprising that the non-amyloidogenic rIAPP also forms similar helical structure when bound to membranes
(Knight, et al. 2006). The hIAPP1-19 and rIAPP1-19 fragments reconstitued in DPC micelles have also been
shown to adopt -helical structure (Nanga, et al. 2008). In addition, it was found that in solution, rIAPP has
a tendency to sample -helical structures (Williamson, et al. 2007). The acceleration of hIAPP fibril
formation in the presence of helix-promoting organic solvents like TFE and HFIP support the importance
of helical structure in the process of fibril formation (Padrick, et al. 2002). The observation of -helical
structure in membrane-bound hIAPP seems an ordinary observation, since it is known that many peptides
adopt -helical structure when interacting with a lipid bilayer (Shai 1999). However, this helical structure
might turn out to be extra-ordinary, in view of the observation that the hIAPP monomer converts from a
mostly unstructured peptide in solution to a -sheet rich fibrillar assembly. Particularly interesting is the
suggestion that this -helical state could be an intermediate that promotes fibril formation of hIAPP
(Knight, et al. 2006). This suggestion deserves consideration and needs more research, in particular because
it would suggest alternative, -helix based ways to inhibit cytotoxicity, next to the “established” design of
disrupters of -sheet structure as a means to prevent aggregation and cytotoxicity.
Future directions
There has been considerable progress in the field of hIAPP-membrane interaction during the past five
years, however it is still far from clear how these interactions relate to cytotoxicity in T2DM. Various
hypotheses have been put forward, and all of them are logical starting points for further research.
Discrepancies in studies of cytotoxicity and membrane interaction of hIAPP species most likely result
from ill-defined or impure hIAPP samples, for example those containing traces of pre-existing aggregates
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(Konarkowska, et al. 2006), or synthesis-related residues of mercury (Cobb, et al. 1992; Golpon, et al.
2003). Due to the often rapid and uncontrollable aggregation of amyloidogenic proteins and peptides, the
possibility of dissociation of species from fibril ends (Carulla, et al. 2005), or the recently proposed lipid-
induced fibril dissociation into oligomers (Martins, et al. 2008), it is difficult to obtain a pure, structurally
uniform sample of either monomers, oligomers or fibrils. Efforts are likely to be directed towards
dissecting the structural heterogeneity in hIAPP amyloid formation, specifically considering polymorphism
observed in oligomeric species and fibrils. One way of obtaining pure samples with a single morphology
would be the use of novel purification strategies, and specific antibodies can be of great help in identifying
unique (oligomeric) hIAPP species, for example the oligomer-specific antibodies pioneered by the Glabe
group (Glabe 2004). The ability to isolate such hIAPP species is crucial for future studies that attempt to
link structure to cytotoxicity. Another way of tackling the large variety of intermediate species is using
techniques that can resolve several different species in one sample, for example single-molecule
techniques. Recent examples have shown the strength of these techniques for solving heterogeneity in
populations of amyloidogenic peptides and proteins (Collins, et al. 2004; Mukhopadhyay, et al. 2007;
Kostka, et al. 2008; Orte, et al. 2008).
As mentioned before, various studies have shown that it is not necessarily a particular species that can
be cytotoxic, but that the conversion from one species to another could also be cytotoxic. Future studies
into these ‘amyloid conversions’, in particular membrane-mediated conversions, could reveal new insights
into cytotoxic mechanisms. One particularly helpful tool is the use of molecular modeling, which has
recently been successfully adapted for amyloidogenic proteins interacting with membranes (Friedman, et
al. 2009). It is clear from many recent studies that the effects of membranes and other interfaces on amyloid
aggregation can be huge, and warrant future investigations.
Many of the membrane permeability assays are distant from the membrane conditions found in vivo.
Efforts to extrapolate results and hypotheses from model-membrane systems towards physiological -cell
membranes are likely to increase. Morphology and structure from in vivo produced hIAPP oligomers and
fibrils would provide valuable insight in the physiological relevance of the species and processes that have
now mostly been obtained using synthetic peptides and test-tube conditions. Only this, physiologically
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relevant information will bring us closer to the development of inhibitors for hIAPP-induced cytotoxic
processes in the Islets of Langerhans.
Studies on hIAPP cytotoxicity can increasingly benefit from the growing knowledge obtained from
other amyloidogenic systems. Still, there are convincing reasons to assume that cytotoxic mechanisms and
aggregation pathways are not necessarily the same for the different amyloid-related peptides and proteins.
Consequently, one might have to consider stepping away from the hypothesis that a generic mechanism
exists that describes amyloid-induced cytotoxicity for all misfolding diseases.
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Figure legends
Fig. 1. IAPP structure and morphology. (a) Amino acid sequence of hIAPP and non-amyloidogenic rodent
IAPP (rIAPP). Both peptides are C-terminally amidated and have a disulfide bond between residues 2 and
7. Residues in red mark the differences between hIAPP and rIAPP. The blue line indicates residues
involved in the fibril core while the green line marks residues which are thought to be involved in
membrane interactions (b) Negatively stained electron microscopy image of in vitro assembled hIAPP
fibrils showing different fibril morphologies: ribbon-like fibrils and coiled fibrils. Image kindly provided
by U. Aebi and C. Goldsbury. (c) Model of an hIAPP fibril based on NMR data of a morphologically
homogeneous fibril sample. The picture shows a cross-sectional view of the fibril, with 2 hIAPP monomers
back to back. The long-axis of the fibril is perpendicular to the plane of the paper. Reprinted with
permission from (Luca, et al. 2007). Copyright 2007 American Chemical Society. (d) Example of the
morphology and size-distribution of in vitro assembled spherical hIAPP oligomers. Reprinted with
permission from (Kayed, et al. 2004). Copyright 2004 by the American Society for Biochemistry and
Molecular Biology. (e) Example of the morphology of an in vitro assembled annular hIAPP oligomer.
18
Reprinted with permission from (Porat, et al. 2003). Copyright 2003 American Chemical Society. (f)
Atomic force microscopy (AFM) image of two membrane-incorporated hIAPP oligomers that display a
pore-like structure. Reprinted with permission from (Quist, et al. 2005). Copyright 2005 National Academy
of Sciences, U.S.A.
Fig. 2. Electron micrograph showing a mat of islet amyloid fibrils (A) next to a -cell (B) in human Islets
of Langerhans. Bundles of fibrils penetrate the -cell membrane (arrows). The characteristic secretory
vesicles that store insulin and hIAPP are clearly visible as circular structures with an electron dense black
spot inside (arrowheads). Magnification 19500X. Reprinted with kind permission from the author and
Springer Science and Business Media (Westermark 1973).
Fig. 3. Scheme showing various suggested membrane-permeabilizing hIAPP species and processes in
relation to cytotoxic hIAPP-membrane interaction. Predominantly unstructured (grey circle), -helix rich
(blue triangle) and -sheet rich (green rectangles) hIAPP monomers or oligomers are participating in and/or
converted during aggregation at or near membranes. Stars show the membrane permeabilization events,
with yellow stars suggesting membrane permeabilization by toxic species and red stars suggesting
membrane permeabilization by toxic processes. Route 1 symbolizes membrane permeabilization by
preformed -sheet rich oligomers (Kayed, et al. 2004) or by the bigger -sheet rich annular oligomers that
insert in the membrane (1a)(Kayed, et al. 2009). Alternatively, such oligomers could assemble in the
membrane from hIAPP monomers (1b)(Quist, et al. 2005). Route 2 describes the binding of initially
random-coil hIAPP monomers to lipids, followed by folding into helical structure and the formation of -
helix-rich on-pathway oligomers that permeabilize the membrane (Knight, et al. 2006). Route 3 starts by
binding of monomer to the membrane followed by the participation of monomers and/or oligomers in fibril
growth at the membrane. The process of fibril elongation at the membrane results in membrane
permeabilization (Engel, et al. 2008).
Fig. 4. Cryo EM image of hIAPP fibrils (arrows) that are associated with disrupted large unilamellar
vesicles (LUVs) composed of phospholipids (asterisks) after initially monomeric hIAPP was allowed to
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aggregate in the presence of LUVs. Pre-formed hIAPP fibrils did not cause membrane disruption.
Reprinted with permission from (Engel, et al. 2008). Copyright 2008 National Academy of Sciences,
U.S.A.
Fig. 5. Model for the structure of monomeric membrane-bound hIAPP from EPR data. The red ribbon
indicates the -helical part of the peptide (residues 9-20). The N-terminal and C-terminal part are
unstructured. The scheme shows the position of the peptide relative to the bilayer lipids. Reprinted with
permission from (Apostolidou, et al. 2008). Copyright 2008 by the American Society for Biochemistry and
Molecular Biology.
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